No, PTU Does Not Need to Be Held on the Day of Routine Thyroid Function Testing
There is no recommendation in clinical guidelines or FDA labeling to hold propylthiouracil on the day of blood draw for routine thyroid function monitoring. Patients should continue their regular PTU dosing schedule when having labs drawn.
Rationale for Continuous Dosing
The American Thyroid Association/American Association of Clinical Endocrinologists guidelines explicitly address monitoring of antithyroid drugs without any mention of holding medication before testing 1. The monitoring protocol is straightforward:
- Initial phase: Check free T4 approximately 4 weeks after starting therapy, then every 4-8 weeks until euthyroid levels are achieved
- Maintenance phase: Once euthyroid, monitor every 2-3 months with free T4 and TSH
- T3 monitoring: May also be checked since free T4 can normalize while T3 remains elevated
The goal is to assess the patient's thyroid status while on their current medication regimen, not to measure thyroid function in the absence of treatment. Holding PTU would defeat this purpose and provide misleading results that don't reflect actual disease control.
Pharmacokinetic Considerations
PTU has a relatively short half-life with biexponential elimination (distribution phase t½ ≈ 4 hours, elimination phase t½ ≈ 2.6 days) 2. However, thyroid hormone levels respond to sustained drug effect over days to weeks, not acute dosing. The FDA label emphasizes that "thyroid function tests should be monitored periodically during therapy" without any instruction to hold medication 3.
What Actually Matters for Monitoring
The guidelines focus on different monitoring priorities 1:
For safety monitoring:
- Obtain CBC with differential during febrile illness or pharyngitis (to detect agranulocytosis)
- Check liver function tests if symptoms of hepatotoxicity develop (anorexia, jaundice, right upper quadrant pain, dark urine)
- Routine monitoring of CBC or liver enzymes is NOT recommended
For efficacy monitoring:
- Continue regular dosing to assess therapeutic effect
- Adjust PTU dose based on results to maintain euthyroid state
Common Pitfall to Avoid
Do not confuse PTU monitoring with other medications that require holding before testing (such as biotin before thyroid function tests, or levothyroxine before certain assessments). PTU is fundamentally different—you are monitoring the treated state, not the underlying disease activity in isolation.
The only time PTU should be discontinued is when serious adverse effects occur (agranulocytosis, severe hepatotoxicity, vasculitis) or when transitioning to alternative therapy 1, 3.